Hematologic Oncology | Specialty

Dr. Westin on Response Rates in the JULIET Trial for DLBCL

September 14th 2019

Jason Westin, MD, discusses patient responses with relapsed/refractory diffuse large B-cell lymphoma in the JULIET trial who were treated with tisagenlecleucel.

Update Spotlights Tisagenlecleucel Developments in DLBCL

September 14th 2019

Tisagenlecleucel maintained strong rates of response and duration of response in adults with relapsed/refractory diffuse large B-cell lymphoma, according to the latest findings from the phase II JULIET study presented at the 2019 SOHO Annual Meeting.

Despite Challenges, Targeted Cellular Therapies Continue to Be Explored in AML

September 13th 2019

John F. DiPersio, MD, PhD, discusses the challenges in research surrounding targeted cellular therapies for acute myeloid leukemia

Checkpoint Inhibition Before HSCT Improves PFS Without Increasing Toxicity in R/R Hodgkin Lymphoma

September 13th 2019

The use of checkpoint inhibitors prior to haploidentical stem cell transplantation improved progression-free survival and reduced the risk for relapse for patients with relapsed or refractory Hodgkin lymphoma, according to results from a retrospective study presented at the 2019 SOHO Annual Meeting.

Future of PI3K Inhibition in FL and CLL

September 13th 2019

PI3K Inhibitors in Management of R/R Follicular Lymphoma

September 13th 2019

PI3K Inhibitors in Management of CLL

September 13th 2019

Common Toxicities With PI3K Inhibition

September 13th 2019

Role of PI3K Inhibitors in Treatment of B-cell Malignancies

September 13th 2019

Maintenance CC-486 Improves OS in Newly Diagnosed AML

September 13th 2019

Maintenance therapy with CC-486 (oral azacitidine) led to a highly statistically significant and clinically meaningful improvement in overall survival compared with placebo in patients with newly diagnosed acute myeloid leukemia who achieved first complete response or CR with incomplete blood count recovery with induction therapy.

New Approaches Are Needed to Boost CAR Therapies in ALL

September 13th 2019

Novel strategies are needed to enhance the efficacy of CAR T-cell therapies in patients with acute lymphoblastic leukemia, including new constructs that target more than 1 antigen.

Dr. Rosen on the Emergence of Novel Therapies and Research With IO in Hematologic Malignancies

September 12th 2019

Steven T. Rosen, MD, Irell & Manella Cancer Center Director's Distinguished Chair, Morgan & Helen Chu Director's Chair of the Beckman Research Institute, provost and chief scientific officer, director of the Comprehensive Cancer Center, Beckman Research Institute, and Irell & Manella Graduate School of Biological Sciences, and professor in the Department of Hematology and Hematopoietic Cell Transplantation, at City of Hope, discusses the emergence of novel therapies and the incorporation of immuno-oncology (IO) drugs in hematologic malignancies.

Dr. Smith on Emerging Therapies in Indolent Lymphoma

September 11th 2019

Mitchell R. Smith, MD, PhD, professor of medicine, George Washington University, associate center director for clinical investigations, Division of Hematology and Oncology, GW Cancer Center, discusses emerging therapeutic approaches in indolent lymphoma.

Dr. Snyder Discusses Ongoing Research in Myelofibrosis

September 6th 2019

David S. Snyder, MD, associate chair, Department of Hematology and Hematopoietic Cell Transplantation, professor, Hematology and Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses ongoing research in myelofibrosis.

Dr. Levis on Gilteritinib in Relapsed/Refractory FLT3-Mutated AML

September 6th 2019

Mark James Levis, MD, PhD, program leader of Hematologic Malignancies and Bone Marrow Transplant Program at Sidney Kimmel Comprehensive Cancer Center, and professor of oncology, Johns Hopkins Medicine, discusses an analysis of gilteritinib in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia harboring other common co-mutations or a high FLT3-internal tandem duplication allelic ratio.

Blood Cancer Treatment Continues to Shift Away From Chemotherapy

September 6th 2019

Steven T. Rosen, MD, discusses the rapid evolution in hematologic cancer treatment and highlighted challenges that have recently emerged.

Research Flourishes in Hematologic Malignancies at City of Hope

September 5th 2019

Experts from City of Hope share insight on some of the pivotal research being conducted at their institution.

Challenges Remain, But Research Abounds in Polycythemia Vera and Myelofibrosis

September 3rd 2019

David S. Snyder, MD, highlights agents currently undergoing clinical trials for polycythemia vera and myelofibrosis as well as how to most effectively treat patients using transplantation.

Dr. Moreau on the CASSIOPEIA Trial in Transplant-Eligible Myeloma

August 30th 2019

Phillippe Moreau, MD, head, Hematology Department, university professor of clinical hematology, University Hospital of Nantes, France, discusses the phase III CASSIOPEIA trial in transplant-eligible multiple myeloma.

Dr. Pemmaraju on the Ongoing Trial of Tagraxofusp in Myelofibrosis

August 30th 2019

Naveen Pemmaraju, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the ongoing phase I/II trial of tagraxofusp (SL-401; Elzonris) in patients with intermediate- or high-risk relapsed/refractory myelofibrosis.